Evidence that antibody-mediated neutralization of human immunodeficiency virus type 1 by sera from infected individuals is independent of coreceptor usage
about
Interactions between natural killer cells and antibody Fc result in enhanced antibody neutralization of human immunodeficiency virus type 1.Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage.Study of the V3 loop as a target epitope for antibodies involved in the neutralization of primary isolates versus T-cell-line-adapted strains of human immunodeficiency virus type 1Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.Increased neutralization sensitivity and reduced replicative capacity of human immunodeficiency virus type 1 after short-term in vivo or in vitro passage through chimpanzees.A cell line-based neutralization assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or the CXCR4 coreceptor.Characterization of primary isolate-like variants of simian-human immunodeficiency virusVaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelopeInduction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques.Differential CD4/CCR5 utilization, gp120 conformation, and neutralization sensitivity between envelopes from a microglia-adapted human immunodeficiency virus type 1 and its parental isolate.Patterns of changes in human immunodeficiency virus type 1 V3 sequence populations late in infection.Human immunodeficiency virus type 1 variants isolated from single plasma samples display a wide spectrum of neutralization sensitivityNeutralization profiles of sera from human immunodeficiency virus (HIV)-infected individuals: relationship to HIV viral load and CD4 cell count.The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection.A versatile vector for the production of pseudotyped viruses expressing gp120 antigens from different clades of primary HIV-1 isolates.Systemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels.Antibody-dependent cell-mediated cytotoxicity in simian immunodeficiency virus-infected rhesus monkeysPostexposure immunoprophylaxis of primary isolates by an antibody to HIV receptor complex.Increased neutralization sensitivity of recently emerged CXCR4-using human immunodeficiency virus type 1 strains compared to coexisting CCR5-using variants from the same patient.Humoral Immune Pressure Selects for HIV-1 CXC-chemokine Receptor 4-using Variants.Derivation and characterization of a simian immunodeficiency virus SIVmac239 variant with tropism for CXCR4.Immunogenicity of constrained monoclonal antibody A32-human immunodeficiency virus (HIV) Env gp120 complexes compared to that of recombinant HIV type 1 gp120 envelope glycoproteins.Comparison of the antibody repertoire generated in healthy volunteers following immunization with a monomeric recombinant gp120 construct derived from a CCR5/CXCR4-using human immunodeficiency virus type 1 isolate with sera from naturally infected iNeutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage.Neutralizing antibodies in sera from macaques immunized with attenuated simian immunodeficiency virus.Continued utilization of CCR5 coreceptor by a newly derived T-cell line-adapted isolate of human immunodeficiency virus type 1Reversal of human immunodeficiency virus type 1 IIIB to a neutralization-resistant phenotype in an accidentally infected laboratory worker with a progressive clinical course.Antibody binding and neutralization of primary and T-cell line-adapted isolates of human immunodeficiency virus type 1.Antibody-mediated enhancement of human immunodeficiency virus type 1 infectivity is determined by the structure of gp120 and depends on modulation of the gp120-CCR5 interactionHuman immunodeficiency virus type 1 primary isolate neutralization resistance is associated with the syncytium-inducing phenotype and lower CD4 cell counts in subtype CRF01_AE-infected patients.
P2860
Q33781055-718EA0EE-1A1E-4D77-8EC2-7FB98254B506Q33783714-BD2C7046-942B-4B53-A46A-0BC800779874Q33786049-3A5C11E6-10F4-4AB2-8397-E59C5356AEA0Q33788810-7FDCF769-FFCA-4EB3-9255-106FFEA3846FQ33810203-918448F1-F728-45A7-85F1-C51ECFFEF26DQ33822395-EB2BC87F-0EB8-4803-A9E6-4166376ADA96Q33825229-0B2816D3-3D9F-4FE3-B6B4-18ED6ADE5A7AQ33839402-CE278EB9-284A-47B3-B94B-F2710C542609Q33842286-C833ED49-A8EE-4157-8273-CD4502DEFFCEQ33851094-6A4FFA79-736D-428B-9DFF-1FA946711AF9Q33874171-B711BBBC-933F-471F-9CC6-4E4A4F0104CEQ33987391-D4F8C591-8041-4E1C-A54F-1D6DE88675D8Q33998352-770E7F7D-0048-4965-A506-C4042DA8EAA2Q34317025-FA9F6FA8-08B3-4324-8E8E-7A92B2210229Q34444535-0CEA95E4-C69D-44D6-B02C-0641460F42C2Q34546037-6151B3AE-1C51-41C8-82B6-5A0000C237BBQ35077793-CFFF8B4D-9226-44BE-BBAE-E9CDAECE3081Q35621250-5C296883-B5C5-469B-8578-7ACFF28CE270Q35634988-5937BDAF-B210-4C6A-B5E3-BB28B005E844Q37034798-7E2730BE-19B0-4A10-B1FE-B5E2B2FCE1BCQ37356010-91A4DD39-80CA-4D87-9469-F4441ACD4007Q37730028-674C1EA3-ECA7-4639-ADCE-11CD074AF9E7Q39549660-58177230-B013-46EF-A899-8D089ABED3FCQ39577692-D57C9DAE-C5E2-4DA4-B8D1-811B0725D673Q39579973-959FA327-869B-4B3F-BE19-477521A0D321Q39580513-B2111713-ECDD-46E1-ADFD-411653B4F01EQ39605628-5E66F2B7-AEAA-443E-89F5-9CDA64210960Q39610187-D57B2921-50BE-426C-B732-1B8A4D33F2DEQ39682713-D1B3A746-4FD5-47B0-AA1C-CA608994234DQ39789278-B98666B7-A16D-41B2-ADB4-8C893F010288
P2860
Evidence that antibody-mediated neutralization of human immunodeficiency virus type 1 by sera from infected individuals is independent of coreceptor usage
description
1998 nî lūn-bûn
@nan
1998 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի մարտին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Evidence that antibody-mediate ...... ndependent of coreceptor usage
@ast
Evidence that antibody-mediate ...... ndependent of coreceptor usage
@en
type
label
Evidence that antibody-mediate ...... ndependent of coreceptor usage
@ast
Evidence that antibody-mediate ...... ndependent of coreceptor usage
@en
prefLabel
Evidence that antibody-mediate ...... ndependent of coreceptor usage
@ast
Evidence that antibody-mediate ...... ndependent of coreceptor usage
@en
P2093
P2860
P1433
P1476
Evidence that antibody-mediate ...... ndependent of coreceptor usage
@en
P2093
D C Montefiori
D P Bolognesi
R G Collman
P2860
P304
P577
1998-03-01T00:00:00Z